Patent · US Active

Inhibition of AXL signaling in anti-metastatic therapy

US8618254B2 · kind B2 · utility

22Cited by

4References

8Claims

0Family size

Assignee

The Board of Trustees of the Leland Stanford Junior University · US

Inventors

Amato J. Giaccia · Stanford, US
Erinn Bruno Rankin · Waltham, US
Jennifer R. Cochran · Stanford, US
Douglas Jones · Newton, US
Mihalis Kariolis · South San Francisco, US
Katherine Fuh · Chesterfield, US
Yu Miao · Sunnyvale, US

Key dates

Filing date	Jul 20, 2012
Grant date	Dec 31, 2013
Priority date	—
Expiry date	Jul 22, 2032

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL and its ligand GAS6.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.